This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|November 18, 2020
Watson-Marlow Reveals Plans for New Facility in Cork, Ireland
Author(s)BioPharm International Editors
Watson-Marlow Limited Ireland has revealed plans for a new ISO 14644-1 Class 7 cleanroom to be added to the company’s existing site in Cork, Ireland.
Advertisement
Watson-Marlow Limited Ireland has revealed plans for a new facility in Cork, Ireland. The plans for a new ISO 14644-1 Class 7 cleanroom to be added to the company’s existing site in Cork were announced in a Nov. 16, 2020 press release.
The new facility will be certified to meet the regulatory demands of the pharmaceutical and biopharmaceutical manufacturing sector in Ireland. Once completed, the new facility will give customers of Watson-Marlow, based in Ireland, local access to essential bioprocess single-use assemblies for biopharmaceutical production.
In the press release, Denis Coll, biopharm sector manager—Ireland, said, “We’re delighted to build on our presence in Cork, reflecting the wealth of talent and opportunity available and the importance of Ireland in the growth of the global biopharmaceutical industry. Our puresu single-use assemblies harness Watson-Marlow’s extensive experience in biopharmaceutical processing, and the new facility will provide biotech and pharma manufacturing organizations in Ireland with specifically designed, validated products to support their innovation. The new ISO accredited facility offers a sustainable, Ireland-based supply chain that reflects Watson-Marlow’s commitment to engineering a sustainable future.”
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
4
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
5